The Court noted that the agreement provided exceptions to the no-challenge covenants for “any patent . . . asserted (or threatened to be asserted) against it or its products,” and where “there is a ...
Sometimes the best way to fix a mistake is to double down on it—and that is just what DexCom is doing with its continuous glucose monitors for diabetes patients. It’s a decision that should pay off ...
DexCom shares took a slight tumble after earnings were announced Thursday evening off of strong results. Guidance for the year was upgraded due to growing demand and FDA clearance for the Apple Watch ...
Predictions of a sales-growth slowdown sent DexCom stock tumbling this summer. Management predicted third-quarter sales would rise by just 1% to 3% year over year. Two of DexCom's top competitors ...
Abbott Laboratories and Dexcom are the biggest players in the market for continuous glucose monitoring devices. Abbott has a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results